USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Institut National de la Sante et de la Recherche Medicale (INSERM)

USPTO PatentsView assignee record - 617 granted patents across 89 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

RSS updates for this company

The verdict

According to USPTO PatentsView, Institut ranks #738 of 49,997 tracked US assignees by granted-patent volume, with 617 patents across 89 technology areas.

#738
of 49,997 US assignees by volume
Top 3%
by Innovation Score (61.8/100)
13.6
avg claims per patent
+9%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R738 · Foreign Corporation #738 · 617 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

  • GRANTS-MID 617 grants
  • TOP-DECILE #738/49,997
  • PHOTO-FINISH InvenSense
  • CPC-WIDE A61K · 89 areas
  • INNOV-STRONG 61.8/100
  • CLAIMS-RICH 13.6 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-FLAT +9% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: InvenSense, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Institut

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Institut's Innovation Score is 61.8/100 (top 3% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

How Institut's grant cadence moved

Between 2020–2024, Institut National de la Sante et de la Recherche Medicale (INSERM) received 300 grants versus 274 in 2015–2019 (+9% equal-window velocity, above median growth). Across complete PatentsView years, output peaked in 2020 at 77 grants and bottomed in 2024 at 43. Lead class A61K accounts for 58.5% of the portfolio across 89 subclasses. Volume neighbours: Baxter International Inc. (#734) and Uchicago Argonne, LLC (#742).

Institut's three-year grant acceleration

From 2019–2021 to 2022–2024, Institut National de la Sante et de la Recherche Medicale (INSERM) moved from 179 to 174 grants (0.97x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,262. See the growth leaderboard.

Who files at Institut's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Institut holds 617 patents at rank #738, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Institut

By rank, the assignees closest to #738 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Institut's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Institut, neither rank-band nor same-CPC leaders (those blocks stay above).

Institut's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

62 Top 3% higher than 97% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

4050607080 20152016201720182019202020212022202320242025 43
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Institut National de la Sante et de la Recherche Medicale (INSERM) patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 57 9.2%
2016 52 8.4%
2017 60 9.7%
2018 52 8.4%
2019 53 8.6%
2020 77 12.5%
2021 49 7.9%
2022 62 10.0%
2023 69 11.2%
2024 43 7.0%
2025partial year 43 7.0%

Which technologies does Institut National de la Sante et de la Recherche Medicale (INSERM) patent most?

Top 15 of 89 technology areas

Where it ranks

Overall rank by patents

#738

of 49,997 tracked assignees

Innovation Score

61.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Institut National de la Sante et de la Recherche Medicale (INSERM)'s patent record in context - here's where to go next.

  • Institut National de la Sante et de la Recherche Medicale (INSERM)'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 58.5% of its portfolio - see every assignee active in that class. Explore A61K
  • Ranked #738 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Institut National de la Sante et de la Recherche Medicale (INSERM) against Baxter International Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 61.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.